Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568463 | 0.86 | GPR119 (0.50) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL13117125 | 0.85 | GPR119 (0.49) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL3560832 | 0.85 | GPR119 (0.49) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL3562191 | 0.84 | GPR119 (0.48) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL1458887 | 0.79 | GPR119 (0.76) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL2708676 | 0.79 | GPR119 (0.52) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL2889077 | 0.77 | GPR119 (0.52) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL15579067 | 0.76 | HTT (0.63) | CKS1BSKP1SKP2GPR119JAK2 | |
| SCHEMBL13117128 | 0.76 | ACHE (0.49) | CKS1BSKP1SKP2GPR119ALDH1A1 | |
| SCHEMBL26986642 | 0.75 | ALDH1A1 (0.67) | CKS1BSKP1SKP2GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | CKS1B 1110/4885SKP1 926/4885SKP2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.